查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016446

专业学名药市场报告：按给药途径、适应症、分销管道和地区划分（2026-2034 年）

Specialty Generics Market Report by Route of Administration, Indication, Distribution channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球专业非专利市场规模达892亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到1,876亿美元，2026年至2034年的复合年增长率（CAGR）为8.36%。推动市场成长的因素众多，包括旨在整合能力、资源和市场份额的策略联盟日益增多，线上药局和远端医疗平台的蓬勃发展，以及有利的政府政策。

特效法非专利是指价格昂贵的品牌特效药的非专利药版本。这些药物用于治疗癌症、类风湿性关节炎、多发性硬化症和爱滋病等复杂慢性疾病。它们与传统生物製药，需要特殊的处理和给药方式（通常为注射剂），并且透过有限的分销网络销售。由于涉及的分子结构复杂且生产流程先进，特效法学名药的研发面临独特的挑战。因此，其核准流程可能比传统学名药更为严格。此外，非专利在医疗保健领域非专利巨大的潜力。它们在以更低的成本为患者提供必要的治疗的同时，也减轻了医疗保健系统的经济负担。

先进分销管道（例如线上药局和远端医疗平台）的发展也推动了专科学名药市场的成长。这些管道方便了患者取得药品，确保偏远地区的患者也能获得所需的药物。此外，政府医疗保健计划和私人保险公司也不断寻求控制医疗成本飙升的策略。强调使用学名药，尤其是专科学名药，是这些关键策略之一。因此，许多政府和保险公司现在鼓励或强制要求在有条件的情况下使用学名药，从而刺激了需求。此外，由于价格实惠，专科非专利在许多地区正成为首选，使更多人能够获得必要的治疗。因此，这极大地支撑了市场。另外，针对更细分和专业疾病的非专利的生产也促进了市场发展。此外，旨在利用合作伙伴公司的能力、资源和市场地位的策略联盟也提振了市场前景。

专业非专利市场的趋势与驱动因素：

对价格合理的医疗保健解决方案的需求日益增长

随着世界人口增长和非传染性疾病（NCDs）负担加重，人们对价格合理的医疗保健解决方案的需求日益增长。专业非专利产业在满足这一需求方面具有独特的优势。专业非专利与品牌药具有生物等效性，能够以更低的成本为患者和医疗保健系统提供与创新药物相同的疗效。此外，包括日本、美国和许多欧洲国家在内的已开发国家人口老化加剧，慢性病的发生率不断上升。这些疾病通常需要长期且复杂的治疗方案，这会对个人和国家医疗保健系统造成沉重的经济负担。在开发中国家，中产阶级的壮大及其对先进医疗保健解决方案日益增长的需求也给现有的医疗基础设施带来了压力。

品牌药品专利到期

推动专业学名药产业发展的最重要因素之一是品牌药专利到期。一旦专利失效，其他生产商就可以生产和销售这些药物的非专利药版本。由于学名药的研发成本通常低于新药，因此可以在保持疗效的同时，以更实惠的价格提供仿製药。每年，销售额达数十亿美元的药物都会失去专利保护。这为专业非专利生产商提供了一个进入成熟市场和现有消费群的绝佳机会。因此，这些药物的可近性得到改善，使更多人受益，尤其是中低收入家庭，并对市场产生正面影响。

药物研发中的技术进步

专业学名药产业正与整个製药产业同步发展。近年来，药物研发和生产技术的进步使得生产更复杂的学名药（例如生物相似药）成为可能，而这些药物先前难以生产。此外，人工智慧和先进分析技术等工具正在简化这些药物的研发流程。这意味着专业学名药生产商现在能够应对比以往任何时候都更广泛的疾病和症状。而且，生产流程的创新确保了这些药物的品质稳定，并符合全球监管机构制定的严格标准。因此，这正在推动市场发展。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：全球特药非专利市场：引言

第五章：为什么专业学名药如此盈利？

第六章：全球特药学名药市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场区隔：依给药途径
  • 市场区隔：依指标
  • 市场区隔：依分销通路划分
  • 市场区隔：按地区
  • 市场预测
  • SWOT分析
  • 价值链分析
  • 波特五力分析
  • 关键市场驱动因素与成功因素

第七章 市场区隔：依给药途径

  • 注射药物
  • 口服
  • 其他的

第八章 市场区隔：依适应症划分

  • 肿瘤学
  • 自体免疫疾病
  • 感染疾病
  • 其他的

第九章 市场区隔：依分销通路划分

  • 零售药房
  • 专科药房
  • 医院药房

第十章 市场区隔：依地区划分

  • 北美洲
    • 市场概览
    • 市场表现
    • 市场细分：按国家/地区
      • 我们
      • 加拿大
    • 市场预测
  • 欧洲
    • 市场概览
    • 市场表现
    • 市场细分：按国家/地区
      • 义大利
      • 德国
      • 法国
      • 英国
      • 西班牙
    • 市场预测
  • 亚太地区
    • 市场概览
    • 市场表现
    • 市场细分：按国家/地区
      • 日本
      • 中国
      • 印度
      • 韩国
    • 市场预测
  • 拉丁美洲
    • 市场概览
    • 市场表现
    • 市场细分：按国家/地区
      • 巴西
      • 墨西哥
    • 市场预测
  • 中东和非洲
    • 市场概览
    • 市场表现
    • 市场预测

第十一章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Amneal Pharmaceuticals LLC
    • Apotex Corp.
    • Bausch Health Companies Inc.
    • Dr. Reddy's Laboratories Ltd
    • Endo International plc.
    • Hikma Pharmaceuticals PLC
    • Mallinckrodt Pharmaceuticals
    • Sandoz Group AG
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: SR112026A1219

The global specialty generics market size reached USD 89.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 187.6 Billion by 2034, exhibiting a growth rate (CAGR) of 8.36% during 2026-2034. There are various factors that are driving the market, which include rising number of strategic collaborations aiming to leverage the capabilities, resources, and market presence, the evolution of online pharmacies and telemedicine platforms, and favorable government initiatives.

Specialty generics refer to generic versions of high-cost, brand-name specialty drugs. These medications are used to treat complex, chronic conditions such as cancer, rheumatoid arthritis, multiple sclerosis, and HIV. They differ from traditional generics in that they are typically biologic-based, require special handling and administration often injectables, and are often distributed through limited networks. The development of specialty generics presents unique challenges due to the intricate nature of the molecules involved and the complex processes used in their manufacturing. As a result, regulatory pathways for their approval can be more stringent compared to conventional generic drugs. In addition, specialty generics hold immense potential in healthcare. They offer patients access to vital treatments at a reduced cost, while also alleviating the financial burden on healthcare systems.

The evolution of advanced distribution channels, such as online pharmacies and telemedicine platforms, has also propelled the growth of the specialty generics market. These channels facilitate easy access to medications, ensuring patients in even remote locations can obtain the drugs they need. Along with this, government healthcare programs and private payers are continuously seeking strategies to contain escalating healthcare costs. Emphasizing the use of generic drugs, especially specialty generics, is a primary strategy. Therefore, several governments and insurance companies now incentivize or mandate the prescription of generics where available, thereby driving demand. In addition, specialty generics, being more affordably priced, have become the preferred choice for many in regions, ensuring essential treatments are within reach of larger segments of the population. Thus, this is significantly supporting the market. Apart from this, the production of generics for more niche, and specialized conditions is contributing to the market. Moreover, strategic collaborations aiming to leverage the capabilities, resources, and market presence of partnering entities are creating a positive market outlook.

Specialty Generics Market Trends/Drivers:

Increasing Demand for Affordable Healthcare Solutions

As the global population continues to rise and the burden of non-communicable diseases (NCDs) expands, there's a significant push to provide affordable healthcare solutions. The specialty generics industry is uniquely poised to address this demand. Specialty generics, which are bioequivalent versions of brand-name drugs, offer patients and healthcare systems the therapeutic efficacy of innovative medicines but at a reduced cost. Additionally, aging populations in various developed countries, such as Japan, the United States, and numerous European nations, are leading to an increased incidence of chronic diseases. These conditions often require prolonged and complex treatment regimens, which can be financially taxing for both individuals and national healthcare systems. Furthermore, in developing nations, the expansion of middle-class populations and their demand for advanced healthcare solutions is putting a strain on existing infrastructures.

Patent Expirations of Branded Drugs

One of the most significant drivers of the specialty generics industry is the expiration of patents for branded drugs. When patents expire, it opens the door for other manufacturers to produce and market generic versions of those medications. Given that research and development (R&D) costs for generics are typically lower than for novel drugs, these medications can be priced more affordably while maintaining therapeutic efficacy. Each year, drugs with billions of dollars in annual sales lose patent protection. This presents a golden opportunity for specialty generic manufacturers to tap into established markets with a ready consumer base. Thus, the accessibility of these medications then benefits the wider population, especially those in low-to-middle-income households, positively influencing the market.

Technological Advancements in Drug Development

The specialty generics industry is evolving with the broader pharmaceutical sector. Along with this, recent technological advancements in drug development and manufacturing are enabling the production of more complex generics, such as biosimilars, which were previously challenging to produce. In addition, tools, such as artificial intelligence and advanced analytical methodologies have streamlined the research and development (R&D) process for these drugs. This means that specialty generic manufacturers now address a broader range of diseases and conditions than ever before. Furthermore, innovations in manufacturing processes are ensuring that these drugs are produced with consistent quality, meeting the rigorous standards set by global regulatory bodies. As a result, it is also contributing to the market.

Specialty Generics Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with specialty generics market forecast at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on route of administration, indication, and distribution channel.

Breakup by Route of Administration:

  • Injectables
  • Oral
  • Others

Injectable dominates the market

The injectables route of administration has emerged as a significant market driver within the specialty generics industry. This growth can be attributed to the increasing prevalence of chronic diseases and complex medical conditions. Injectables offer advantages, including precise dosing and rapid onset of action, making them suitable for managing critical health conditions. In addition, the expiration of patents for certain branded biologics and specialty drugs has opened doors for generic manufacturers to enter the market with cost-effective alternatives. Moreover, the rising focus on research and development in the pharmaceutical sector has led to innovative injectable products with improved therapeutic outcomes. These market drivers collectively contribute to the growth and prominence of the injectables route of administration in the specialty generics industry.

On the contrary, the oral route of administration plays a pivotal role as a market driver within the specialty generics industry, due to the changing consumer preferences. Numerous patients prefer oral formulations due to ease of administration, eliminating the need for injections and reducing potential discomfort. Along with this, the vast array of chronic diseases and conditions requiring long-term treatment has contributed to the popularity of oral drugs.

Breakup by Indication:

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

Oncology dominates the market

The rising prevalence of cancer continues to rise globally, necessitating a constant demand for effective and affordable oncology treatments. With an increasing number of patients requiring long-term therapies, the accessibility and cost-effectiveness of specialty generics become essential in improving cancer care. In addition, the expiration of patents for several branded oncology drugs has opened opportunities for generic manufacturers to enter the market, offering more affordable alternatives without compromising on quality. Apart from this, advancements in research and technology have led to the development of innovative formulations and drug delivery systems, enhancing the efficacy and patient compliance of oncology generics. Moreover, government initiatives and policies aimed at reducing the burden of cancer by promoting generic drug usage have further propelled market growth.

On the other hand, the infectious diseases route of administration has emerged as a crucial market driver within the specialty generics industry, influenced by the ongoing global burden of infectious diseases, including outbreaks and pandemics, has underscored the urgent need for effective and accessible treatment options.

Breakup by Distribution channel:

  • Retail Pharmacies
  • Specialty Pharmacies
  • Hospital Pharmacies

Retail pharmacies dominates the market

The retail pharmacies distribution channel plays a pivotal role as a market driver within the specialty generics industry, primarily influenced by the widespread presence of retail pharmacies ensuring convenient and accessible distribution of specialty generic medications to a broader patient base. As these pharmacies are typically located in various communities and neighborhoods, patients can easily access their prescribed medications without the need for specialized healthcare facilities. In addition, the rising prevalence of chronic diseases and the growing demand for long-term treatment options have amplified the significance of retail pharmacies in delivering specialty generics. Furthermore, the retail pharmacies' established relationships with healthcare providers allow for streamlined communication and collaboration, facilitating efficient prescription processing and patient care. As the demand for specialty generics continues to grow, retail pharmacies' essential role in distribution and patient support is set to reinforce the industry's expansion and accessibility to critical medications.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Europe
  • Italy
  • Germany
  • Spain
  • United Kingdom
  • France
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest specialty generics market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Europe (Italy, Germany, France, United Kingdom, and Spain); Asia Pacific (Japan, China, India, and South Korea); Latin America (Brazil, Mexico); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North America region is driven by the increasing prevalence of chronic diseases and complex medical conditions. It is leading to a growing demand for specialized treatment options. Specialty generics, with their cost-effective alternatives to branded specialty drugs, have gained traction in managing these conditions effectively. Additionally, the expiration of patents for certain branded specialty medications has created opportunities for generic manufacturers to enter the market, providing patients with more affordable treatment options. In addition, favorable government policies and initiatives aimed at promoting the use of generic medications have supported the expansion of the specialty generics industry in North America. These policies encourage generic drug usage, leading to enhanced patient access and overall cost savings in the healthcare system. Moreover, advancements in research and development leading to the introduction of innovative specialty generics with improved therapeutic outcomes are positively influencing the market.

Competitive Landscape:

The global specialty generics market is experiencing significant growth due to the escalating investments in research and development to develop innovative formulations, drug delivery systems, and combination therapies to improve the efficacy and patient compliance of their products. Ensuring compliance with regulatory standards and obtaining necessary approvals from health authorities in various countries is a critical aspect for specialty generic companies to launch and market their products. Along with this, the expansion of product portfolios to cover a wider range of therapeutic areas, such as oncology, immunology, and rare diseases, to cater to diverse patient needs is positively influencing the market. Apart from this, companies are offering patient support programs that provide counseling, adherence assistance, and financial aid to patients, thereby improving patient outcomes and medication adherence. Furthermore, collaborating with pharmaceutical companies, research institutions, and healthcare organizations allows specialty generics companies to access new technologies is contributing to the market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.

Some of the key players in the market include:

  • Teva Pharmaceuticals Industries
  • Akorn, Inc.
  • Mylan N.V.
  • Mallinckrodt
  • Sandoz International GmbH
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals
  • Apotex Corp.
  • Endo International plc

Key Questions Answered in This Report

1. What is the size of the global specialty generics market?

2. What are the key factors driving the global specialty generics market?

3. What has been the impact of COVID-19 on the global specialty generics market?

4. What is the breakup of the global specialty generics market based on the route of administration?

5. What is the breakup of the global specialty generics market based on the indication?

6. What is the breakup of the global specialty generics market based on the distribution channel?

7. What are the key regions in the global specialty generics market?

8. Who are the key players/companies in the global specialty generics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Global Specialty Generics Market: Introduction

5 Why are Specialty Generics So Lucrative?

6 Global Specialty Generics Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Breakup by Route of Administration
  • 6.5 Market Breakup by Indication
  • 6.6 Market Breakup by Distribution Channel
  • 6.7 Market Breakup by Region
  • 6.8 Market Forecast
  • 6.9 SWOT Analysis
    • 6.9.1 Overview
    • 6.9.2 Strengths
    • 6.9.3 Weaknesses
    • 6.9.4 Opportunities
    • 6.9.5 Threats
  • 6.10 Value Chain Analysis
  • 6.11 Porters Five Forces Analysis
    • 6.11.1 Overview
    • 6.11.2 Bargaining Power of Buyers
    • 6.11.3 Bargaining Power of Suppliers
    • 6.11.4 Degree of Competition
    • 6.11.5 Threat of New Entrants
    • 6.11.6 Threat of Substitutes
  • 6.12 Key Market Drivers and Success Factors

7 Market Breakup by Route of Administration

  • 7.1 Injectable
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Autoimmune Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialty Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Hospital Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Overview
    • 10.1.2 Market Performance
    • 10.1.3 Market Breakup by Country
      • 10.1.3.1 United States
        • 10.1.3.1.1 Market Trends
        • 10.1.3.1.2 Market Forecast
      • 10.1.3.2 Canada
        • 10.1.3.2.1 Market Trends
        • 10.1.3.2.2 Market Forecast
    • 10.1.4 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Overview
    • 10.2.2 Market Performance
    • 10.2.3 Market Breakup by Country
      • 10.2.3.1 Italy
        • 10.2.3.1.1 Market Trends
        • 10.2.3.1.2 Market Forecast
      • 10.2.3.2 Germany
        • 10.2.3.2.1 Market Trends
        • 10.2.3.2.2 Market Forecast
      • 10.2.3.3 France
        • 10.2.3.3.1 Market Trends
        • 10.2.3.3.2 Market Forecast
      • 10.2.3.4 United Kingdom
        • 10.2.3.4.1 Market Trends
        • 10.2.3.4.2 Market Forecast
      • 10.2.3.5 Spain
        • 10.2.3.5.1 Market Trends
        • 10.2.3.5.2 Market Forecast
    • 10.2.4 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Overview
    • 10.3.2 Market Performance
    • 10.3.3 Market Breakup by Country
      • 10.3.3.1 Japan
        • 10.3.3.1.1 Market Trends
        • 10.3.3.1.2 Market Forecast
      • 10.3.3.2 China
        • 10.3.3.2.1 Market Trends
        • 10.3.3.2.2 Market Forecast
      • 10.3.3.3 India
        • 10.3.3.3.1 Market Trends
        • 10.3.3.3.2 Market Forecast
      • 10.3.3.4 South Korea
        • 10.3.3.4.1 Market Trends
        • 10.3.3.4.2 Market Forecast
    • 10.3.4 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Market Overview
    • 10.4.2 Market Performance
    • 10.4.3 Market Breakup by Country
      • 10.4.3.1 Brazil
        • 10.4.3.1.1 Market Trends
        • 10.4.3.1.2 Market Forecast
      • 10.4.3.2 Mexico
        • 10.4.3.2.1 Market Trends
        • 10.4.3.2.2 Market Forecast
    • 10.4.4 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Overview
    • 10.5.2 Market Performance
    • 10.5.3 Market Forecast

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 Amneal Pharmaceuticals LLC
    • 11.3.2 Apotex Corp.
    • 11.3.3 Bausch Health Companies Inc.
    • 11.3.4 Dr. Reddy's Laboratories Ltd
    • 11.3.5 Endo International plc.
    • 11.3.6 Hikma Pharmaceuticals PLC
    • 11.3.7 Mallinckrodt Pharmaceuticals
    • 11.3.8 Sandoz Group AG
    • 11.3.9 Sun Pharmaceutical Industries Ltd.
    • 11.3.10 Teva Pharmaceutical Industries Ltd.
    • 11.3.11 Viatris Inc.

List of Figures

  • Figure 1: Global: Specialty Generics Market: Major Drivers and Challenges
  • Figure 2: Global: Specialty Generics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Specialty Generics Market: Breakup by Route of Administration (in %), 2025
  • Figure 4: Global: Specialty Generics Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Specialty Generics Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Specialty Generics Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Specialty Generics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Specialty Generics Industry: SWOT Analysis
  • Figure 9: Global: Specialty Generics Industry: Value Chain Analysis
  • Figure 10: Global: Specialty Generics Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Specialty Generics Market (Administration through Injectables): Sales Value (in Billion USD), 2020 & 2025
  • Figure 12: Global: Specialty Generics Market (Administration through Injectables) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 13: Global: Specialty Generics Market (Oral Administration): Sales Value (in Billion USD), 2020 & 2025
  • Figure 14: Global: Specialty Generics Market (Oral Administration) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 15: Global: Specialty Generics Market (Other Routes of Administration): Sales Value (in Billion USD), 2020 & 2025
  • Figure 16: Global: Specialty Generics Market (Other Routes of Administration) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 17: Global: Specialty Generics Market (Oncology): Sales Value (in Billion USD), 2020 & 2025
  • Figure 18: Global: Specialty Generics Market (Oncology) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 19: Global: Specialty Generics Market (Autoimmune Diseases): Sales Value (in Billion USD), 2020 & 2025
  • Figure 20: Global: Specialty Generics Market (Autoimmune Diseases) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 21: Global: Specialty Generics Market (Infectious Diseases): Sales Value (in Billion USD), 2020 & 2025
  • Figure 22: Global: Specialty Generics Market (Infectious Diseases) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 23: Global: Specialty Generics Market (Other Indications): Sales Value (in Billion USD), 2020 & 2025
  • Figure 24: Global: Specialty Generics Market (Other Indications) Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 25: Global: Specialty Generics Market: Sales Through Retail Pharmacies (in Billion USD), 2020 & 2025
  • Figure 26: Global: Specialty Generics Market Forecast: Sales Through Retail Pharmacies (in Billion USD), 2026-2034
  • Figure 27: Global: Specialty Generics Market: Sales Through Specialty Pharmacies (in Billion USD), 2020 & 2025
  • Figure 28: Global: Specialty Generics Market Forecast: Sales Through Specialty Pharmacies (in Billion USD), 2026-2034
  • Figure 29: Global: Specialty Generics Market: Sales Through Hospital Pharmacies (in Billion USD), 2020 & 2025
  • Figure 30: Global: Specialty Generics Market Forecast: Sales Through Hospital Pharmacies (in Billion USD), 2026-2034
  • Figure 31: North America: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Europe: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Europe: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Italy: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Italy: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Germany: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Germany: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: France: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: France: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: United Kingdom: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: United Kingdom: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Spain: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Spain: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Asia Pacific: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Asia Pacific: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Japan: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Japan: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: China: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: China: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: India: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: India: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: South Korea: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: South Korea: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Latin America: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Latin America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Brazil: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Brazil: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Mexico: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Mexico: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Middle East and Africa: Specialty Generics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Middle East and Africa: Specialty Generics Market: Breakup by Country (in %), 2025
  • Figure 67: Middle East and Africa: Specialty Generics Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Specialty Generics Market Forecast: Breakup by Route of Administration (in Billion USD), 2026-2034
  • Table 3: Global: Specialty Generics Market Forecast: Breakup by Indication (in Billion USD), 2026-2034
  • Table 4: Global: Specialty Generics Market Forecast: Breakup by Distribution Channel (in Billion USD), 2026-2034
  • Table 5: Global: Specialty Generics Market Forecast: Breakup by Region (in Billion USD), 2026-2034
  • Table 6: North America: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 7: Europe: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 8: Asia Pacific: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 9: Latin America: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 10: Middle East and Africa: Specialty Generics Market: Key Industry Highlights, 2025 and 2034
  • Table 11: Global: Specialty Generics Market Structure
  • Table 12: Global: Specialty Generics Market: Key Players